image credit: Adobe Stock

Manufacturing issues spur FDA to deny approval of Lilly colitis drug

April 14, 2023


Mirikizumab is one of a slate of anticipated drug launches Lilly is relying on to add billions more to its yearly sales totals.

Others include the fast-selling diabetes drug Mounjaro — which could soon be cleared as a weight-loss treatment — as well as the Alzheimer’s medicine donanemab and the eczema treatment lebrikizumab. In January, its cancer drug Jaypirca was approved for mantle cell lymphoma.

Read More on Biopharma Dive